Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | BTK | Q06187 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782276 | 0.91 | EGFR (0.59) | TNK2EGFRBTKCYP3A4CDK4 | |
| SCHEMBL1780904 | 0.88 | EGFR (0.56) | TNK2EGFRBTKCYP3A4CDK4 | |
| SCHEMBL1782666 | 0.86 | EGFR (0.51) | EGFRBTKCYP3A4ALKIGF1R | |
| SCHEMBL1780670 | 0.82 | TTK (0.62) | PTK2CDK4CCNA2CCND1CDK2 | |
| SCHEMBL3663805 | 0.78 | TNK2 (0.55) | TNK2PTK2EGFRJAK3SRC | |
| SCHEMBL1781441 | 0.77 | TTK (0.73) | EGFRBTKCDK4CCNA2CCND1 | |
| SCHEMBL1780091 | 0.77 | TTK (0.57) | TNK2PTK2EGFRJAK3CCNA2 | |
| SCHEMBL27196789 | 0.76 | CDK4 (0.61) | TNK2PTK2EGFRSRCCCNB2 | |
| SCHEMBL1783576 | 0.75 | CDK4 (0.58) | EGFRSRCCCNB2CCNE2CDK1 | |
| SCHEMBL1781068 | 0.75 | TTK (0.76) | EGFRBTKCYP3A4CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | TNK2 347/4885PTK2 259/4885EGFR 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.